Interferon-alpha2b Induced Bipolar Syndrome in Patient with Melanoma: A Case Report.
- Author:
Soon Tae HONG
1
;
Sun Young LEE
;
Jae Nam BAE
;
Min Hee KANG
;
Chul Soo KIM
;
Chul Eung KIM
Author Information
1. Department of Psychiatry, School of Medicine, Inha University, Incheon, Korea. kce320@inha.ac.kr
- Publication Type:Case Report
- Keywords:
Interferon;
Melanoma;
Adverse effect;
Mania;
Mood instability
- MeSH:
Bipolar Disorder;
Depression;
Humans;
Interferons;
Melanoma*;
United States Food and Drug Administration
- From:Journal of Korean Neuropsychiatric Association
2004;43(4):481-484
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The use of a high dose regimen of interferon (INF) has recently been demonstrated to benefit patients with malignant melanoma and the use of high dose INF for stage IIB and III melanoma was approved by Food and Drug Administration in 1995. The therapeutic benefits of INF are sometimes hampered by their severe and troublesome adverse effects including depression, mania, and cognitive impairment. The authors report a melanoma patient treated with adjuvant INF-alpha2b who developed a manic-depressive syndrome or mood instability with therapy and we reviewed literatures on mania and mixed affective syndrome associated with INF.
